Plasminogen Activator Treatment Alone and in Combination in a Rat Embolic Model of Effects of a Selective CD11b/CD18 Antagonist and Recombinant Human Tissue
نویسندگان
چکیده
Stroke Plasminogen Activator Treatment Alone and in Combination in a Rat Embolic Model of Effects of a Selective CD11b/CD18 Antagonist and Recombinant Human Tissue Print ISSN: 0039-2499. Online ISSN: 1524-4628 Copyright © 2003 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Stroke doi: 10.1161/01.STR.0000077016.55891.2E 2003;34:1790-1795; originally published online June 12, 2003; Stroke. http://stroke.ahajournals.org/content/34/7/1790 World Wide Web at: The online version of this article, along with updated information and services, is located on the
منابع مشابه
Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke.
BACKGROUND AND PURPOSE We evaluated the neuroprotective effect of UK-279,276 (also referred to as recombinant neutrophil inhibitory factor), a selective CD11b/CD18 antagonist, in combination with thrombolytic therapy on focal cerebral ischemia. METHODS Male Wistar rats (n=88) were subjected to embolic middle cerebral artery occlusion. Animals were randomly assigned to the following groups (n=...
متن کاملOptimizing refolding condition for recombinant tissue plasminogen activator
Low molecular size additives such as L-arginine and the redox compounds have been used both in the culturemedium and in vitro refolding to increase recombinant proteins production. Additives increase proteinrefolding and yield of active proteins by suppressing aggregate formation or enhancing refolding process.In this work, a comparative study was performed on refolding of rec...
متن کاملDual frequency ultrasound-enhanced tissue plasminogen activator thrombolysis in an in vitro human clot model
Introduction: Stroke causes death and disability in patients throughout the world. At present, the only FDA- approved drug for ischemic stroke is recombinant tissue plasminogen activator (rt- PA). Unfortunately, rtPA can cause intracerebral hemorrhage and must use within limited time window (within 3-4.5 hour after onset of stroke). Ultrasound with rtPA loaded liposomes (rtPA_L...
متن کاملبررسی اثر اولتراسوند بر صدمات ایسکمی مغزی در مدل ترومبوآمبولیک سکته مغزی در رت
Background: Ultrasound (US) has been used in neuroprotection after cerebral ischemia however, its use is controversial. Application of US in combination with fibrinolytic agents may improve fibrinolytic effects. In this study the effects of US, alone or in combination with tissue plasminogen activator (tPA), on brain ischemic injury were examined and we studied whether US is protective in the b...
متن کاملA clinical study investigating the three months prognosis of patients with ischemic stroke treated with recombinant tissue plasminogen activator (rt-PA) and its effective factors
Objective: Currently, treating ischemic stroke by intravenous thrombolytic therapy has acceptable results in patients with stroke. This study aimed to evaluate the three months prognosis of patients treated with recombinant tissue plasminogen activator (rt-PA).Methods: This cross-sectional prospective study was conducted on 30 patients with cerebral ischemic stroke with the National Insti...
متن کامل